Similarly, ramucirumab, another second-line option, has shown better outcomes in advanced HCC with AFP > 400 ng/ml previously treated with sorafenib, leading international drug agencies to approve this anti-VEGF drug in this setting (80). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.